Vaccines
Case-control study | Effectiveness of COVID-19 vaccines against infection and mortality in children in Argentina.
2 Dec, 2022 | 14:36h | UTC
M-A | Efficacy and safety of COVID-19 inactivated vaccine.
1 Dec, 2022 | 14:00h | UTCEfficacy and safety of COVID-19 inactivated vaccine: A meta-analysis – Frontiers in Medicine
Joint consensus statement on the vaccination of adult and pediatric hematopoietic stem cell transplant recipients.
30 Nov, 2022 | 13:39h | UTC
M-A | Cardioprotective effects of influenza vaccination in patients with high risk of cardiovascular disease.
25 Nov, 2022 | 12:47h | UTCCardioprotective effects of influenza vaccination among patients with established cardiovascular disease or at high cardiovascular risk: a systematic review and meta-analysis – European Journal of Preventive Cardiology (free for a limited period)
Related:
RCT | Influenza vaccine to reduce adverse vascular events in patients with heart failure.
RCT | Influenza vaccine to reduce adverse vascular events in patients with heart failure.
18 Nov, 2022 | 13:26h | UTCCommentary:
Flu vaccines cut pneumonia, cardiovascular issues in heart failure patients – CIDRAP
Flu Shot Could Be Lifesaver for Folks With Heart Failure – HealthDay
RCT | Evaluation of mRNA-1273 vaccine in children 6 months to 5 years of age.
20 Oct, 2022 | 12:35h | UTC
Commentary on Twitter
Randomized, placebo-controlled trial of the 2-dose @moderna_tx vaccine in children 6 months to 5 years, during Omicron. Safe in ~4,800 kids; good immune response; efficacy vs infections ?https://t.co/DkLXAQQaeZ @NEJM pic.twitter.com/ettWOnDGQf
— Eric Topol (@EricTopol) October 19, 2022
Myocarditis after BNT162b2 vaccination in Israeli adolescents.
20 Oct, 2022 | 12:34h | UTCMyocarditis after BNT162b2 Vaccination in Israeli Adolescents – New England Journal of Medicine
Commentary on Twitter
Among Israeli adolescents between 12 and 15 years of age who received the BNT162b2 vaccine, 9 cases of mild myocarditis were observed, mainly after the second dose. https://t.co/OatYqN4IPD pic.twitter.com/c96d1o7wnt
— NEJM (@NEJM) October 19, 2022
Pooled analysis of cohort studies | Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters.
19 Oct, 2022 | 14:28h | UTCCommentaries:
Prioritisation of COVID-19 boosters in the omicron era – The Lancet
COVID booster halved severe illness, but some groups still at higher risk – CIDRAP
Case-control study | Odds of hospitalization for COVID-19 after 3 vs. 2 doses of mRNA vaccine by time since booster dose.
19 Oct, 2022 | 14:27h | UTC
Incidence of myocarditis/pericarditis following mRNA COVID-19 vaccination among children and younger adults in the US.
13 Oct, 2022 | 13:51h | UTC
Commentary on Twitter (thread – click for more)
Let me me perfectly clear about the evidence for myocarditis after mRNA vaccines
1. There is a notable increased incidence, age 12-39, males, with each dose (Table)https://t.co/XXQbyeLiSP pic.twitter.com/wLTZT3fppy— Eric Topol (@EricTopol) October 12, 2022
Commentary on Twitter
Let me me perfectly clear about the evidence for myocarditis after mRNA vaccines
1. There is a notable increased incidence, age 12-39, males, with each dose (Table)https://t.co/XXQbyeLiSP pic.twitter.com/wLTZT3fppy— Eric Topol (@EricTopol) October 12, 2022
RCT | Immunogenicity and safety of one-dose human papillomavirus vaccine vs. two or three doses.
29 Sep, 2022 | 13:21h | UTCInvited Commentary: HPV vaccines: when one plus one equals three – The Lancet Global Health
Related:
RCT: Single-dose HPV vaccination found effective among young African women.
Three-year follow-up of 2-dose versus 3-dose HPV vaccine
Opinion: A Single-dose HPV Vaccine Would Have a Big Impact on Cancer Prevention
Another Observational Study Suggests One Dose of HPV Vaccine may be Enough
Another Study Suggesting One Dose of HPV Vaccine may be Effective for Prevention of Cervical Cancer
Large Observational Study Suggests One Dose of HPV Vaccine May Be as Effective as Three
Impact of routine childhood immunization in reducing vaccine-preventable diseases in the US.
21 Sep, 2022 | 13:11h | UTC
RCT | A double-dose influenza vaccination during hospitalization for acute coronary syndrome did not improve outcomes compared to standard-dose outpatient vaccination.
13 Sep, 2022 | 13:19h | UTC
Commentary on Twitter
In the VIP-ACS trial, among patients hospitalised with an ACS, double dose influenza vaccination before discharge does not reduce cardiovascular and pulmonary outcomes compared with standard dose vaccination ?https://t.co/L9e7MXWfWV#EHJ #ESCCongress @ehj_ed @rladeiraslopes pic.twitter.com/95o50krrwm
— European Society of Cardiology Journals (@ESC_Journals) August 31, 2022
Study raises concerns about the effectiveness of the monkeypox vaccine.
6 Sep, 2022 | 14:39h | UTCStudy raises concerns about the effectiveness of the monkeypox vaccine – STAT
Original Study (Preprint): Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals – medRxiv
FDA authorizes updated COVID boosters from Moderna and Pfizer.
5 Sep, 2022 | 14:36h | UTCFDA authorizes updated COVID boosters from Moderna and Pfizer – CIDRAP
FDA News Release: Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose – U.S. Food & Drug Administration
Review | Covid-19 vaccines — immunity, variants, boosters.
1 Sep, 2022 | 11:57h | UTCCovid-19 Vaccines — Immunity, Variants, Boosters – New England Journal of Medicine
Long-term follow up of a RCT | Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine.
24 Aug, 2022 | 13:53h | UTCPrecancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Virological replacement & clinical unmasking are two phenomena of interest following #HPVvaccination. We show that clinical unmasking might attenuate long-term reductions in cervical precancer following successful implementation of HPV vax programs in highly screened populations https://t.co/Z7dGQNG1kG
— Monica Sierra (@MonicaSSierra) June 14, 2022
WHO Guidance | Behavioral and social drivers of vaccination: tools and practical guidance for achieving high uptake.
22 Aug, 2022 | 12:13h | UTC
UK approves updated Moderna vaccine targeting Omicron variant.
16 Aug, 2022 | 13:49h | UTCUK approves updated Moderna vaccine targeting Omicron variant – Associated Press/MedicalXpress
See also: Covid: UK first country to approve dual-strain vaccine – BBC
M-A | Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course.
15 Aug, 2022 | 12:21h | UTCInvited Commentary: Infant BCG vaccination is beneficial, but not sufficient – The Lancet Global Health
News Release: BCG vaccine prevents tuberculosis in young children, but not adults – Boston University School of Public Health
Commentary from the author on Twitter (thread – click for more)
1/n Our new @LancetGH study investigating BCG vaccination in infancy and tuberculosis risk is out!
Link: https://t.co/Gu469QlnFh pic.twitter.com/yRIdb2I7Zr
— Leo Martinez (@LeoMarti_EpiTB) August 9, 2022
RCT | Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi.
15 Aug, 2022 | 11:55h | UTCCommentaries:
New TCV data from Malawi highlight longer-term immune response – Coalition Against Typhoid
Related:
Randomized Trial: Efficacy Analysis of a Typhoid Conjugate Vaccine
Cohort Study | Incidence of acute chest syndrome in children with sickle cell disease following implementation of the 13-valent pneumococcal conjugate vaccine.
3 Aug, 2022 | 13:53h | UTC
Commentary on Twitter
#OrigInvestigation: Reduction of acute chest syndrome incidence in children with sickle-cell disease following 13-valent pneumococcal conjugate vaccine (PCV13) implementation in France. https://t.co/MuG6T0g5FU
— JAMA Network Open (@JAMANetworkOpen) August 2, 2022
Retrospective Cohort Study | Effectiveness of a fourth dose of mRNA COVID-19 vaccine against all-cause mortality in long-term care facility residents and in the oldest old.
25 Jul, 2022 | 13:03h | UTCRelated:
Cohort Study | Taiwan’s nationwide Hepatitis B vaccination and antiviral therapy program reduced end-stage liver disease burden.
25 Jul, 2022 | 12:54h | UTC
Commentary on Twitter
This cohort study found the nationwide implementation of hepatitis B vaccination (1984) and antiviral treatment programs (2003) was followed by dramatic reductions in the burden of end-stage liver disease in Taiwan. https://t.co/Qnei2abi85
— JAMA Network Open (@JAMANetworkOpen) July 18, 2022
Cohort Study | Effectiveness of the Pfizer vaccine against Omicron in children 5 to 11 years of age.
21 Jul, 2022 | 13:28h | UTC